onCyt Microbiology AG

onCyt Microbiology AG develops automated online flow cytometry solutions that enhance bioprocess analytics through real-time monitoring and advanced sample handling technologies. Founded in 2017 and headquartered in Zurich, Switzerland, onCyt Microbiology AG specializes in innovative flow cytometry solutions. The company is led by co-founders Michael Besmer and Samuel Wüthrich, who have a background in advanced biotechnology. onCyt has engaged in one total deal, with its most recent funding round occurring on May 25, 2020.

onCyt Microbiology AG specializes in developing automated online flow cytometry solutions aimed at improving bioprocess analytics through real-time monitoring. Its core offerings include the OC-300 Automation add-on, which facilitates the automation of sample acquisition and preparation, and the OC-400 MicroQuant, an innovative online flow cytometer that provides gentle sample handling and rapid optical detection. These products address the complexities of monitoring vital key performance indicators (KPIs) such as viable cell count, product titer, and cell phenotype across various applications in bioprocess development, cell and gene therapy, fermentation, and water analysis. The company's solutions primarily serve clients in applied research and various industries, including aquaculture, cooling water management, pulp and paper production, and biotechnology, with a clientele spanning Europe, North America, and Asia.

The company's revenue is generated through direct sales of their flagship products, the OC-300 and OC-400, to businesses and research institutions engaged in bioprocess development and related fields. Typically, transactions occur under a B2B model, with clients either purchasing equipment outright or entering into partnerships that may involve ongoing service agreements for support and maintenance. Pricing structures are aligned with the advanced capabilities of the products, reflecting the specialized nature of the technology. This revenue model supports the company's growth by ensuring continuous engagement with clients, facilitating innovation, and responding to the evolving needs within the industries they serve.

Following their Series A funding round in May 2020, onCyt Microbiology AG plans to expand its product offerings, including the launch of new flow cytometry solutions designed to further enhance bioprocess monitoring capabilities. The company aims to penetrate new markets in Asia and North America by 2023, leveraging the recent funding to support product development and market entry efforts. This strategy includes the enhancement of their existing product line and the introduction of innovative technologies aimed at meeting the growing demand in the biotechnology sector.